eXoZymes (NASDAQ: EXOZ) closes $5.95M stock and warrant unit offering
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
eXoZymes Inc. completed an underwritten public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds, including a partial exercise of the underwriters’ over-allotment option.
The company sold units combining common shares and warrants, with MDB Capital as sole book‑running manager, and plans to use the net proceeds to advance its N‑trans‑caffeoyltyramine (NCT) program, additional product opportunities, research and development, and general corporate and working capital needs.
Positive
- None.
Negative
- None.
Insights
eXoZymes completes a modest equity unit financing with warrants attached.
eXoZymes raised roughly $5.95 million through a firm commitment underwritten offering of common stock and warrants, including a partial over‑allotment exercise. Units combine equity with leverage via warrants, typical for smaller, R&D‑focused issuers accessing public markets.
The warrants carry an exercise price of $11.24 per share with a potential reset to $0.001 if future equity is sold below $8.99 per share before June 5, 2027. That reset feature can materially increase potential dilution depending on future financing terms.
Proceeds are earmarked for N‑trans‑caffeoyltyramine (NCT) development, additional product opportunities, R&D, and working capital. Actual impact on shareholders will depend on warrant exercises and any future financings that might trigger an exercise price reset.
8-K Event Classification
3 items: 1.01, 7.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Gross proceeds: $5.95 million
Common shares issued: 592,270 shares
Warrants issued: 296,135 warrants
+5 more
8 metrics
Gross proceeds
$5.95 million
Aggregate gross proceeds from the offering including over-allotment units
Common shares issued
592,270 shares
Shares of common stock sold in the firm commitment offering
Warrants issued
296,135 warrants
Warrants to purchase additional common shares issued with units
Over-allotment units
34,440 units
Units purchased on partial exercise of the over-allotment option
Share and warrant prices
$8.99 per share, $0.02 per warrant
Public offering prices disclosed in the press release
Warrant exercise price
$11.24 per share
Initial exercise price for warrants issued in the offering
Potential reset price
$0.001 per share
Warrant exercise price reset if future equity is sold below $8.99 before June 5, 2027
Over-allotment capacity
88,840 shares, 44,420 warrants
Maximum additional securities available under the 45-day over-allotment option
Key Terms
firm commitment underwritten offering, over-allotment option, shelf registration statement, warrants, +2 more
6 terms
firm commitment underwritten offering financial
"pursuant to which the Company issued and sold, in a firm commitment underwritten offering (the “Offering”)"
A firm commitment underwritten offering is when one or more investment banks agree to buy all the new shares or securities from a company and then resell them to investors, guaranteeing the company a fixed amount of cash. Think of it like a retailer buying an entire shipment from a manufacturer before selling it to customers—this gives the company certainty about funding but shifts the resale risk to the banks and typically dilutes existing shareholders, which can affect the stock price.
over-allotment option financial
"The Company granted a 45-day option to MDB to purchase up to 88,840 additional shares of common stock and 44,420 additional Warrants to cover over-allotments"
An over-allotment option is a special agreement that allows underwriters to sell more shares than initially planned if demand is high. Think of it like a retailer offering extra units of a popular product to meet additional customer interest. This option helps ensure the full sale is completed and can also give investors extra shares if they want more.
shelf registration statement regulatory
"The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-292781)"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
warrants financial
"warrants to purchase up to an additional 296,135 shares of Common Stock (the “Warrants”)"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
exercise price financial
"The warrants become exercisable one year from the date of issuance at an exercise price of $11.24 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
prospectus supplement regulatory
"A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC on June 8, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
FAQ
What did eXoZymes (EXOZ) announce in its latest 8-K filing?
eXoZymes announced the closing of an underwritten public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds. The transaction included a partial exercise of the underwriters’ over‑allotment option and was conducted under an effective Form S-3 shelf registration.
How much capital did eXoZymes (EXOZ) raise in the offering?
The company reports gross proceeds of about $5.95 million from the unit offering, including over‑allotment units. This amount is stated before deducting underwriting discounts, commissions, and estimated offering expenses that will reduce the final net proceeds available to eXoZymes.
What securities did eXoZymes (EXOZ) issue in this public offering?
eXoZymes issued common stock and accompanying warrants as units, generally consisting of two shares and one warrant. In total, the company issued 592,270 shares of common stock and 296,135 warrants, plus additional shares and warrants through the partial over‑allotment exercise.
What are the key terms of the eXoZymes (EXOZ) warrants from this deal?
The warrants become exercisable one year after issuance at an exercise price of $11.24 per share and expire five years from issuance. The exercise price may reset to $0.001 if qualifying equity is sold below $8.99 per share before June 5, 2027.
How does eXoZymes (EXOZ) plan to use the offering proceeds?
eXoZymes intends to use net proceeds to support development and commercialization of N‑trans‑caffeoyltyramine (NCT), advance additional product opportunities, fund broader research and development, and provide working capital and other general corporate funds to run and grow its operations.
Under what registration statement was the eXoZymes (EXOZ) offering conducted?
The securities were offered pursuant to an effective Form S-3 shelf registration statement, File No. 333‑292781, which the SEC declared effective on January 23, 2026. A final prospectus supplement and base prospectus describing the offering terms were filed on June 8, 2026.